Deconstructing Exceptional Responses to Immune Checkpoint Inhibition in Recurrent or Metastatic Head and Neck Carcinoma: A Site-Specific Clinical–Biological Synthesis

Abstract

Simple Summary Recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) remains an aggressive disease with historically poor survival rates. Although the introduction of immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 pathway has revolutionized the treatment landscape, only a minority of patients achieve long-term survival. This review explores the clinical and biological profiles of exceptional responders to identify the key factors driving therapeutic success. We analyze how viral drivers (such as HPV and EBV), tumor microenvironment dynamics across anatomical sites, and genomic markers (such as frameshift insertions and deletions) shape immune responsiveness. Additionally, we address the mechanisms of immunotherapy resistance and outline future clinical strategies, such as next-generation checkpoint inhibitors, antibody-drug conjugates, and cancer vaccines, advocating for a transition toward personalized, biomarker-driven oncology.